165 related articles for article (PubMed ID: 37979325)
1. Risk profiles and incidence of cardiovascular events across different cancer types.
Mitchell JD; Laurie M; Xia Q; Dreyfus B; Jain N; Jain A; Lane D; Lenihan DJ
ESMO Open; 2023 Dec; 8(6):101830. PubMed ID: 37979325
[TBL] [Abstract][Full Text] [Related]
2. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data.
Kloner RA; Stanek E; Crowe CL; Singhal M; Pepe RS; Bradsher J; Rosen RC
J Sex Med; 2023 Jan; 20(1):38-48. PubMed ID: 36897243
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
[TBL] [Abstract][Full Text] [Related]
4. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.
Kristensen LE; Strober B; Poddubnyy D; Leung YY; Jo H; Kwok K; Vranic I; Fleishaker DL; Fallon L; Yndestad A; Gladman DD
Ther Adv Musculoskelet Dis; 2023; 15():1759720X221149965. PubMed ID: 36777695
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study.
Abdel-Qadir H; Thavendiranathan P; Austin PC; Lee DS; Amir E; Tu JV; Fung K; Anderson GM
Eur Heart J; 2019 Dec; 40(48):3913-3920. PubMed ID: 31318428
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study.
Li Y; Ong WS; Shwe MTT; Yit NLF; Quek SZH; Pang EPP; Looi WS; Nei WL; Wang MLC; Chua MLK; Tan TWK; Chua ET; Ng CT; Tuan JKL
Cardiooncology; 2022 Mar; 8(1):4. PubMed ID: 35287756
[TBL] [Abstract][Full Text] [Related]
7. A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients.
Cabrera C; Brunelli SM; Rosenbaum D; Anum E; Ramakrishnan K; Jensen DE; Stålhammar NO; Stefánsson BV
BMC Nephrol; 2015 Jul; 16():113. PubMed ID: 26197758
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.
Ware JH; Vetrovec GW; Miller AB; Van Tosh A; Gaffney M; Yunis C; Arteaga C; Borer JS
Am J Ther; 2013; 20(3):235-46. PubMed ID: 23615317
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V; Hallas J; Linder M; Margulis AV; Suehs BT; Arana A; Phiri K; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Xu Y; Kristiansen NS; Appenteng K; de Vogel S; Seeger JD;
Drug Saf; 2021 Aug; 44(8):899-915. PubMed ID: 34236595
[TBL] [Abstract][Full Text] [Related]
11. Risk of Cardiovascular Events Among Patients With Head and Neck Cancer.
Sun L; Brody R; Candelieri D; Lynch JA; Cohen RB; Li Y; Getz KD; Ky B
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):717-725. PubMed ID: 37347472
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control.
Alatorre CI; Hoogwerf BJ; Deeg MA; Nelson DR; Hunter TM; Ng WT; Rekhter MD
Curr Med Res Opin; 2018 Feb; 34(2):337-343. PubMed ID: 29065729
[TBL] [Abstract][Full Text] [Related]
13. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study.
Rodriguez CJ; Swett K; Agarwal SK; Folsom AR; Fox ER; Loehr LR; Ni H; Rosamond WD; Chang PP
JAMA Intern Med; 2014 Aug; 174(8):1252-61. PubMed ID: 24935209
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study.
Wang Y; Gao W; Han X; Jiang J; Sandler B; Li X; Zema C
J Med Econ; 2023; 26(1):1495-1506. PubMed ID: 37902966
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
Reich K; Langley RG; Lebwohl M; Szapary P; Guzzo C; Yeilding N; Li S; Hsu MC; Griffiths CE
Br J Dermatol; 2011 Apr; 164(4):862-72. PubMed ID: 21332467
[TBL] [Abstract][Full Text] [Related]
18. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.
Liao KP; Liu J; Lu B; Solomon DH; Kim SC
Arthritis Rheumatol; 2015 May; 67(8):2004-10. PubMed ID: 25917955
[TBL] [Abstract][Full Text] [Related]
19. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
Nguyen C; Luthra R; Kuti E; Willey VJ
Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
[TBL] [Abstract][Full Text] [Related]
20. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.
Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; de Zeeuw D; Eckardt KU; McMurray JJV; Claggett B; Lewis EF; Pfeffer MA
Am J Kidney Dis; 2017 Oct; 70(4):522-531. PubMed ID: 28599901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
